Grupo para la caracterización molecular de las neoplasias hematológicas

Foto de Grupo para la caracterización molecular de las neoplasias hematológicas

Foto de Vita-Salute San Raffaele University

Vita-Salute San Raffaele University

Milán, Italia

Vita-Salute San Raffaele University-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2023

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
Leukemia, Vol. 37, Núm. 7, pp. 1521-1529

2022

Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)
Clinical Lymphoma, Myeloma and Leukemia

2020

Ascend: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia
Journal of Clinical Oncology